Payment overview · 2025
General Payments
$538.41
26 reported records · 4 companies
Healthcare provider profile · identity verified
Christopher L Snyder, PA
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · CHATTANOOGA, TN · NPI 1124327549
Verified facts
What the public records show
CMS Open Payments records show Christopher L Snyder, PA received $538.41 in general payments during 2025 across 26 reported records.
Gilead Sciences, Inc. accounted for 74.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Ozempic, Rybelsus.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 388 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Descovy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Cabenuva by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $399.70 | 74.2% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.85 | 18.6% | 4 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $22.55 | 4.2% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $16.31 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.41 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Yeztugo Normalized: yeztugo |
Drug | Gilead Sciences, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $101.84 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $99.85 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $99.85 | 4 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $16.31 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 388 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
388 | 66 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 388 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 223 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 218 | 43 |
| Lisinopril | Lisinopril | 151 | 21 |
| Gabapentin | Gabapentin | 146 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 144 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 17 |
| Omeprazole | Omeprazole | 112 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 16 |
| Valacyclovir | Valacyclovir Hcl | 95 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 76 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 67 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 67 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 65 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 60 | suppressed |
| Trulicity | Dulaglutide | 52 | 12 |
| Eliquis | Apixaban | 51 | suppressed |
| Carvedilol | Carvedilol | 46 | suppressed |
| Losartan Potassium | Losartan Potassium | 46 | 12 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 45 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 45 | suppressed |
| Metformin Hcl | Metformin Hcl | 44 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Furosemide | Furosemide | 42 | suppressed |
| Mounjaro | Tirzepatide | 42 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 41 | 11 |
| Spironolactone | Spironolactone | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 11 |
| Buspirone Hcl | Buspirone Hcl | 39 | suppressed |
| Potassium Chloride | Potassium Chloride | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 35 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 35 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 34 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Famotidine | Famotidine | 32 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 31 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 25 | suppressed |
| Tivicay | Dolutegravir Sodium | 25 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 18 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 18 | suppressed |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 17 | suppressed |
| Amoxicillin | Amoxicillin | 16 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 12 |
| Eletriptan Hbr | Eletriptan Hydrobromide | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Fluvastatin Er | Fluvastatin Sodium | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.41 · 26 records | Gilead Sciences, Inc. | Biktarvy, CABENUVA, Ozempic, Rybelsus, Yeztugo | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Gilead Sciences, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error